77313-09-8

Usage

Uses

Used in Pharmaceutical Industry:
Dimethyl 3-aminopentanedioate is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drugs.
Used in Agrochemical Industry:
Dimethyl 3-aminopentanedioate is used as a building block in the creation of agrochemicals, contributing to the development of substances that can enhance crop protection and yield.
Used in Organic Synthesis:
Dimethyl 3-aminopentanedioate is used as a versatile intermediate in organic synthesis for its ability to be incorporated into a wide range of chemical reactions and compound constructions.
Used in Material Development:
Dimethyl 3-aminopentanedioate is used in the development of new materials, leveraging its chemical properties to create innovative substances with potential applications in various industries.
Used in Bioactive Substances Research:
Dimethyl 3-aminopentanedioate is used in the research and development of bioactive substances, exploring its potential to contribute to advancements in medicine and healthcare.

InChI:InChI=1/C7H13NO4/c1-11-6(9)3-5(8)4-7(10)12-2/h5H,3-4,8H2,1-2H3

Upstream product

• 5164-76-1 dimethyl glutaconate 

Downstream Products

• 77856-51-0 dimethyl β-<(benzyloxycarbonyl)amino>glutarate 
• 82803-55-2 3-tert-butoxycarbonylaminopentanedioic acid dimethyl ester 
• 77856-52-1 (S)-3-<(benzyloxycarbonyl)amino>-4-(methoxycarbonyl)butyric acid 
• 77856-53-2 (S)-3-Amino-4-methoxycarbonylbutyric acid 
• 149193-54-4 dimethyl 3-[[4-[[4-(aminoimino-methyl)phenyl]-amino]-1,4-dioxobutyl]amino]pentanedioate 
• 1345984-09-9 diethyl 3-{[2-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)-2-oxoethyl]amino}pentanedioate 
• 1345983-34-7 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]carbonyl}-amino)pentanedioic acid 
• 1345984-11-3 dimethyl 3-({[(3R,5S)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioate 
• 1345982-99-1 3-({[(3R,5S)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid 
• 1345983-47-2 dimethyl 3-({[(3R,5R)-3-butyl-3-ethyl-4-hydroxy-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioate 
• 1345982-69-5 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid 
• 1345983-90-5 dimethyl 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioate 
• 1345983-88-1 dimethyl 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]carbonyl}amino)pentanedioate 
• 1345984-23-7 C₃₁H₄₅N₃O₆S 

Relevant academic research and scientific papers

Iminodipropionic Acid as the Leaving Group for DNA Polymerization by HIV-1 Reverse Transcriptase

Previous studies have demonstrated that some selected amino monoacids and amino diacids can function as leaving groups in the polymerase-catalyzed incorporation of deoxynucleotides into DNA. Among these, the iminodiacetic acid phosphoramidate of deoxyadenosine monophosphate (IDA-dAMP) represents an interesting example, as it could overcome some of the problems observed when using L-aspartic acid as the leaving group, that is, poor chain elongation. We have now synthesized and evaluated a series of IDA-dAMP analogues that bear either an extended aliphatic chain in the amino acid function, or a phosphonic acid moiety (substituting for the carboxylic acid function). Among these compounds, the nucleotide with an iminodipropionic acid leaving group (IDP-dAMP) was identified as the best substrate; the excellent single incorporation (91% conversion to a P+1 strand at 50 μM) was at a substrate concentration ten times lower than that used for IDA-dAMP). This nucleotide also presented improved kinetics and elongation capability compared to IDA-dAMP. The analogues with T, G, and C base moieties were also investigated for their incorporation ability with HIV-1 RT. The incorporation efficiency was found to decrease in the order A>T>G>C. The properties of the iminodipropionic acid as the leaving group surpass those of previously evaluated leaving groups; this acid will be a prime candidate for in vivo testing.